Friday, June 26, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 848 of 1,261

  1. US 8557245

    Methods for treating bone cancer by administering a nerve growth factor antagonist antibody

    Regents of the University of Minnesota · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  2. US 8557290

    Multifunction nanoconjugates for imaging applications and targeted treatment

    Northwestern University · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  3. US 8557839

    Fused ring azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  4. US 8557833

    Aminopyrimidines useful as kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  5. US 8557844

    Substrate reduction therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  6. US 8557822

    Carboxamide, sulfonamide and amine compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  7. US 8557800

    Sphingosine kinase inhibitors

    Apogee Biotechnology Corporation · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  8. US 8557818

    Compounds useful as protein kinase inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  9. US 8557250

    Methods for preparing complex multivalent immunogenic conjugates

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  10. US 8556882

    Inducible interleukin-12

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  11. US 8557291

    Abuse-deterrent pharmaceutical compositions of opioids and other drugs

    Collegium Pharmaceutical, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  12. US 8557298

    Medicaments for chemotherapeutic treatment of disease

    Provectus Pharmatech, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  13. US 8557552

    Selective neuronal nitric oxide synthase inhibitors

    Northwestern University · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  14. US 8557295

    Use of cellular extracts for skin rejuvenation

    REGENICS AS · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  15. US 8557812

    Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  16. US 8557788

    Prevention of tissue ischemia and related compositions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  17. US 8557790

    A3 adenoside receptor agonists for the reduction of intraocular pressure

    CAN-FITE BIOPHARMA LTD. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  18. US 8557789

    Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides

    The United States of America as represented by the Secretary of the Development of Health and Human Services · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  19. US 8557978

    Cross-linked glycopeptide-cephalosporin antibiotics

    Theravance, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  20. US 8557805

    Fused ring compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted

  21. DE 102012205493

    Einen Dopamin-Agonisten enthaltendes transdermales Applikationssystem

    ACINO AG [DE] · Granted Oct 10, 2013 · Expires Oct 5, 2033

    granted

  22. US 8551526

    Preparation of drug particles using evaporation precipitation into aqueous solutions

    The Board of Regents of the University of Texas System · Granted Oct 8, 2013 · Expires Oct 3, 2033

    granted

  23. US 8551936

    Defensin-antigen fusion proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 8, 2013 · Expires Oct 3, 2033

    granted

  24. US 8552018

    Substituted tricyclic compounds as protein kinase inhibitors

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Oct 8, 2013 · Expires Oct 3, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.